NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Core Insights - NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol [1][3] - The company aims to address the unmet need for safe and well-tolerated LDL-lowering therapies, particularly for patients who do not respond adequately to existing treatments [3] Company Overview - NewAmsterdam Pharma is investigating obicetrapib, a low-dose, once-daily CETP inhibitor, in multiple phase 3 trials [3] - The therapy is being studied both as a standalone treatment and in combination with ezetimibe, intended to complement statin therapy for patients with elevated LDL-C [3] Upcoming Events - Ian Somaiya, the Chief Financial Officer, will participate in a virtual fireside chat at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025 [1] - A live webcast of the event will be available on the company's investor relations website, with an archived replay to follow [2]